97 filings
Page 3 of 5
8-K
1gzmty29uhbt8ncn
24 May 21
Departure of Directors or Certain Officers
4:01pm
8-K
w6li64ry6h0r
6 May 21
Collegium Reports Record Quarterly Revenue of $87.7 Million
4:01pm
8-K
zmft zw985v9
25 Feb 21
Collegium Reports Record Full-Year 2020 Revenue of $310.0 Million
4:01pm
8-K
62dpqtkvv6rfljk2uc0
6 Jan 21
Regulation FD Disclosure
4:02pm
8-K
452etkh2lo
30 Dec 20
Departure of Directors or Certain Officers
4:53pm
8-K
v8ncs dtnvemza
5 Nov 20
Collegium Reports Net Income of $11.3 Million in the Third Quarter of 2020
4:14pm
8-K
cea12hj44rutwaax2b3
30 Sep 20
Collegium Announces Settlement with Teva Resolving Xtampza® ER Patent Litigation
8:00am
8-K
9u8b i4apcc7fa
25 Sep 20
Collegium Appoints Rita Balice-Gordon to its Board of Directors
4:03pm
8-K
eukfiqppr5
5 Aug 20
Collegium Reports Net Income of $8.1 Million in the Second Quarter of 2020
4:01pm
8-K
nkobpbq16nblv7fwg
9 Jul 20
Departure of Directors or Certain Officers
5:00pm
8-K
7y1llbxzxzyme5oc8zwk
22 May 20
Submission of Matters to a Vote of Security Holders
4:08pm
8-K
5cmvnl etmy
7 May 20
Collegium Reports First Quarter 2020 Profitability
4:01pm
8-K
lc649w
27 Feb 20
Collegium Reports Full-Year 2019 Revenue of $296.7 Million
4:01pm
8-K
8a9syxhp6 q2a6
13 Feb 20
Collegium Announces Closing of the Nucynta Franchise Acquisition
5:10pm
8-K
qsah z0fb
10 Feb 20
Entry into a Material Definitive Agreement
7:14am
8-K
1hlhrp1dk0 x3kzxi
6 Feb 20
Collegium to Acquire U.S. Rights to Nucynta Franchise
4:11pm
8-K
j5f66ptgjm6b 7kf
7 Jan 20
Regulation FD Disclosure
4:05pm
8-K
vof lueudj
6 Nov 19
Collegium Reports Third Quarter 2019 Financial Results
4:01pm
8-K
bn0k7v9y
7 Aug 19
Collegium Reports Second Quarter 2019 Financial Results
4:01pm
8-K
u4pdycrerj1y1i2 k5m
8 May 19
Collegium Reports First Quarter 2019 Financial Results
4:02pm